<DOC>
	<DOCNO>NCT01253473</DOCNO>
	<brief_summary>The main objective study see use anti-inflammatory patient airway disease chronic obstructive pulmonary disease ( COPD ) phenotype effective use treatment patient loss lung tissue . Symbicort plus ipratropium/albuterol use 12 week open-label study subject airway predominant COPD .</brief_summary>
	<brief_title>Symbicort Airway Predominant Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>Subjects COPDGene study airway-predominant COPD chest CT scan enrol ; total 40 subject plan . Subjects background ipratropium-albuterol administer four time daily . Subjects randomize receive budesonide ( 180 ug twice daily ) formoterol-budesonide ( 160/4.5 ug twice daily ) 12 week . The main objective explore novel outcome : blood biomarkers chest CT scan . Outcomes include lung function , walk distance , respiratory disease-specific health status , expiratory chest CT scan gas trap exploratory outcome . The primary outcome measure FEV1 pre-bronchodilator 12 hour last dose study medication end 12 week treatment . FEV1 measure morning 6 hour last dose ipratropium/albuterol 12 hour last dose budesonide budesonide/formoterol</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>1 . COPD GOLD Stage 2 3 ( postbronchodilator FEV1 3580 % predict FEV1/FVC &lt; 0.7 time enrollment COPDGene ) spirometry . 2 . Less 15 % lung &lt; 950 Hounsfield Units COPDGene highresolution inspiratoryChest CT scan ( i.e . evidence significant emphysema ) 3 . Greater 10 % gas trap COPDGene expiratory CT scan ( i.e . evidence small airway disease ) . 4 . No history recent use ( within pat 8 week ) inhale systemic corticosteroid . 5 . Body weight &lt; 100 kg ( low dose CT scan subject increase boyd weight reliably analyze ) . 1 . Exacerbation COPD respiratory illness require antibiotic within past 8 week . 2 . Previous adverse reaction inhale steroid , longacting beta agonist , longacting anticholinergic medication . 3 . Symptomatic , untreated benign prostate hypertrophy . 4 . Allergy peanut . 5 . Glaucoma</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>COPD</keyword>
</DOC>